Featured Publications
Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders
Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-Analysis: Treatment of Attention-Deficit/Hyperactivity Disorder in Children With Comorbid Tic Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2009, 48: 884-893. PMID: 19625978, PMCID: PMC3943246, DOI: 10.1097/chi.0b013e3181b26e9f.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-AgonistsAtomoxetine HydrochlorideAttention Deficit Disorder with HyperactivityChildComorbidityContraindicationsDose-Response Relationship, DrugDouble-Blind MethodHumansMethylphenidatePropylaminesPsychotropic DrugsRandomized Controlled Trials as TopicTic DisordersTourette SyndromeConceptsAlpha-2 agonistsAttention-deficit/hyperactivity disorderTic symptomsComorbid ticsSupratherapeutic dosesTic disordersADHD symptomsTreatment of ADHDHyperactivity disorderPlacebo-controlled trialEfficacy of medicationsStandardized mean differenceEvidence-based treatmentsHalf of childrenComorbid tic disordersPrimary outcomeDifferent medicationsPsychostimulant medicationPubMed searchTic severityTourette syndromePackage insertsDrug AdministrationAtomoxetineSymptoms
2021
A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome
Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF. A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome. Journal Of Neuropsychiatry 2021, 33: 328-336. PMID: 34340527, DOI: 10.1176/appi.neuropsych.19080178.Peer-Reviewed Original ResearchConceptsTourette syndromeTic symptomsUncontrolled trialsYale Global Tic Severity Scale-Total Tic ScoreDouble-blind placebo-controlled trialAvailable evidence-based treatmentsPhase 2 pilot studyExtension phasePlacebo-controlled trialRefractory Tourette syndromeTotal tic scoreEffective pharmacological treatmentCannabis-derived compoundsEvidence-based treatmentsTHC dosingSecondary outcomesPrimary outcomeComorbid conditionsPharmacological treatmentTic scoreYGTSS scoresTherapeutic combinationsSide effectsTrial designSyndrome
2020
Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review.
Artukoglu BB, Li F, Szejko N, Bloch MH. Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32459404, DOI: 10.4088/jcp.19r12798.Peer-Reviewed Original ResearchConceptsTreatment of TDGreater score reductionPlacebo-controlled trialTardive dyskinesiaVitamin EPharmacologic treatmentTD symptomsScore reductionSystematic reviewPublication biasVesicular monoamine transporter 2 (VMAT2) inhibitorTardive dyskinesia treatmentVitamin E studiesTransporter 2 inhibitorsCalcium channel blockersDuration of treatmentTardive dyskinesia symptomsGreater reductionFixed-effects modelMedication classesHead trialsDyskinesia symptomsPrimary outcomePharmacologic agentsVMAT2 inhibitorsMeta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders
Zhou MS, Nasir M, Farhat LC, Kook M, Artukoglu BB, Bloch MH. Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2020, 60: 35-45. PMID: 32387445, DOI: 10.1016/j.jaac.2020.03.007.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPlacebo-controlled trialPharmacological treatmentPharmacological agentsAvailable pharmacological agentsAutism spectrum disorderSerotonin reuptake inhibitorsStandardized mean differenceStandardized study designsTreatment of ASDPharmacologic treatmentPrimary outcomeReuptake inhibitorsAntipsychotic medicationSpecific assessment toolsFolinic acidSpectrum disorderModest benefitRepetitive behaviorsMean differenceStudy designSmall effect sizesIndividual studiesTrialsPlacebo
2019
N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study
Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study. Journal Of Child And Adolescent Psychopharmacology 2019, 30: 32-37. PMID: 31800306, PMCID: PMC7133418, DOI: 10.1089/cap.2019.0041.Peer-Reviewed Original ResearchConceptsCY-BOCS total scoreN-acetylcysteineYale-Brown ObsessiveTotal scorePlacebo groupNAC groupStudy populationBenefit of NACPlacebo-controlled clinical trialSymptom severityEffect of NACMild adverse eventsOCD symptom severityLarger study populationPediatric obsessive-compulsive disorderSmall pilot studyChildren's Yale-Brown ObsessiveStudy medicationAdverse eventsPrimary outcomeGlutamate dysfunctionObsessive-compulsive disorderWeek 12Future trialsNAC treatment
2017
Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.
Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis. Pain Physician 2017, 20: 353-362. PMID: 28727699.Peer-Reviewed Original ResearchConceptsEfficacy of palmitoylethanolamidePlacebo-controlled trialInactive control conditionsSystematic reviewVisual analog pain scaleAnalog pain scaleSerious adverse eventsEffect of palmitoylethanolamideWeighted mean differenceGreater pain reductionPEA treatmentInactive control groupPain reductionPain scoresAdverse eventsPain scalePain managementPrimary outcomeChronic painConcomitant treatmentControl conditionUseful treatmentAnalgesic agentsPlacebo controlClinical trialsHippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysis
Wilkinson ST, Sanacora G, Bloch MH. Hippocampal Volume Changes Following Electroconvulsive Therapy: A Systematic Review and Meta-analysis. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2017, 2: 327-335. PMID: 28989984, PMCID: PMC5627663, DOI: 10.1016/j.bpsc.2017.01.011.Peer-Reviewed Original ResearchMajor depressive disorderElectroconvulsive therapyTotal hippocampal volumeHippocampal volumeStandardized mean differenceConsistent morphological findingsHippocampal volume increasesCognitive side effectsPre-treatment valuesHippocampal volume changesRandom-effects modelMechanism of actionClinical improvementPrimary outcomeECT treatmentDepressive disorderEffective therapyNeuroplastic processesECT studiesSide effectsAnimal modelsDepression symptomsMeta-AnalysisSystematic reviewMorphological findings
2016
Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. The Journal Of Clinical Psychiatry 2016, 77: e605-11. PMID: 27249090, DOI: 10.4088/jcp.14r09758.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsYale-Brown Obsessive Compulsive ScalePlacebo-controlled trialSerotonin reuptake inhibitorsTreatment of adultsObsessive-compulsive disorderSSRI responseSSRI treatmentReuptake inhibitorsSymptom improvementEfficacy of SSRIsTrials of SSRIsFirst-line pharmacologic treatmentCochrane Central RegisterStart of treatmentMajor depressive disorderEffect of doseObsessive Compulsive ScaleSSRI actionCentral RegisterPharmacologic treatmentPrimary outcomeControlled TrialsSSRI trialDepressive disorderN-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of Child And Adolescent Psychopharmacology 2016, 26: 327-334. PMID: 27027204, PMCID: PMC6445198, DOI: 10.1089/cap.2015.0109.Peer-Reviewed Original ResearchConceptsBenefit of NACEfficacy of NACYale Global Tic Severity ScaleAttention-deficit/hyperactivity disorderObsessive-compulsive disorderTourette syndromeN-acetylcysteineObsessive-compulsive spectrum disordersSide effectsRecent placebo-controlled trialPediatric Tourette syndromePlacebo-controlled trialCurrent pharmacological treatmentsTreatment of ticsTotal tic scoreSeverity of ticsSubstantial side effectsTic Severity ScaleYears of ageMinimal side effectsPediatric TSPrimary outcomeSecondary outcomesGlutamatergic systemPharmacological treatment
2015
LONG‐TERM OUTCOME IN PEDIATRIC TRICHOTILLOMANIA
Schumer MC, Panza KE, Mulqueen JM, Jakubovski E, Bloch MH. LONG‐TERM OUTCOME IN PEDIATRIC TRICHOTILLOMANIA. Depression And Anxiety 2015, 32: 737-743. PMID: 26139231, PMCID: PMC4591183, DOI: 10.1002/da.22390.Peer-Reviewed Original ResearchConceptsPoor long-term prognosisLong-term prognosisLong-term outcomesN-acetylcysteineDepressive symptomsPediatric trichotillomaniaTrichotillomania symptomsOlder ageAdequate symptom reliefPlacebo-controlled trialAnxiety symptomsPredictors of outcomePrevious cross-sectional studiesRisk of depressionCross-sectional studyPrimary outcomeSymptom reliefAcute phaseClinical assessmentTreatment utilizationBaseline evaluationSecondary measuresBaseline assessmentSymptomsBehavioral treatment
2014
Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive–compulsive disorder
Bloch MH, Bartley CA, Zipperer L, Jakubovski E, Landeros-Weisenberger A, Pittenger C, Leckman JF. Meta-analysis: hoarding symptoms associated with poor treatment outcome in obsessive–compulsive disorder. Molecular Psychiatry 2014, 19: 1025-1030. PMID: 24912494, PMCID: PMC4169729, DOI: 10.1038/mp.2014.50.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTreatment responseOCD patientsOdds ratioFurther treatment researchCase-control studyPoor treatment outcomesDifferential treatment responseSymptoms of OCDPrimary outcomeTreatment modalitiesEligible studiesTreatment outcomesPatientsElectronic searchSymptomsTotal participantsBehavioral therapyOCD treatmentDisordersSymptom dimensionsTreatment researchDSM-5Hoarding symptomsTreatmentMeta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Ferracioli-Oda E, Qawasmi A, Bloch M. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. FOCUS The Journal Of Lifelong Learning In Psychiatry 2014, 12: 73-79. DOI: 10.1176/appi.focus.12.1.73.Peer-Reviewed Original ResearchPrimary sleep disordersTotal sleep timeOverall sleep qualityEffect of melatoninSleep disordersSleep qualitySleep latencySleep timeBenign side effect profilePlacebo-controlled trialSide effect profileEfficacy of melatoninTreatment of insomniaSleep onset latencyInfluence of doseDuration of melatoninMelatonin dosePrimary outcomeAbsolute benefitMelatonin usePharmacological treatmentSignificant efficacyNineteen studiesSleep parametersOnset latency
2013
Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLOS ONE 2013, 8: e63773. PMID: 23691095, PMCID: PMC3656905, DOI: 10.1371/journal.pone.0063773.Peer-Reviewed Original ResearchConceptsPrimary sleep disordersTotal sleep timeOverall sleep qualityEffect of melatoninSleep disordersSleep qualitySleep latencySleep timeBenign side effect profilePlacebo-controlled trialSide effect profileEfficacy of melatoninTreatment of insomniaSleep onset latencyInfluence of doseDuration of melatoninMelatonin dosePrimary outcomeAbsolute benefitMelatonin usePharmacological treatmentSignificant efficacyNineteen studiesSleep parametersOnset latencyN-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 231-240. PMID: 23452680, PMCID: PMC3745012, DOI: 10.1016/j.jaac.2012.12.020.Peer-Reviewed Original ResearchConceptsN-acetylcysteinePharmacological interventionsPediatric trichotillomaniaBenefit of NACBehavioral therapySecondary outcome measuresTreatment of childrenClinician-rated improvementMassachusetts General HospitalTreat populationPlacebo groupPrimary outcomeNAC groupGeneral HospitalOutcome measuresTreatment respondersSecondary measuresPlaceboTreatment assignmentTrichotillomaniaLinear mixed modelsTrialsSignificant differencesChildrenTherapyMeta-analysis of LCPUFA Supplementation of Infant Formula and Visual Acuity
Qawasmi A, Landeros-Weisenberger A, Bloch MH. Meta-analysis of LCPUFA Supplementation of Infant Formula and Visual Acuity. Pediatrics 2013, 131: e262-e272. PMID: 23248232, PMCID: PMC3529943, DOI: 10.1542/peds.2012-0517.Peer-Reviewed Original ResearchConceptsInfant visual acuityMonths of ageLCPUFA supplementationVisual acuityInfant formulaTrial methodologic qualitySecondary subgroup analysisVisual acuity developmentVisual resolution acuityPrimary outcomeSubgroup analysisMethodologic qualityUnsupplemented infantsAcuity developmentNineteen studiesCurrent evidenceAcuityResolution acuityBirth statusSecondary analysisPublication biasMean differenceInfantsSupplementationSignificant heterogeneity
2012
Meta-analysis of Long-Chain Polyunsaturated Fatty Acid Supplementation of Formula and Infant Cognition
Qawasmi A, Landeros-Weisenberger A, Leckman JF, Bloch MH. Meta-analysis of Long-Chain Polyunsaturated Fatty Acid Supplementation of Formula and Infant Cognition. Pediatrics 2012, 129: 1141-1149. PMID: 22641753, PMCID: PMC3362904, DOI: 10.1542/peds.2011-2127.Peer-Reviewed Original ResearchConceptsLCPUFA supplementationClinical trialsInfant formulaLong-Chain Polyunsaturated Fatty Acid SupplementationBayley ScalesPolyunsaturated Fatty Acid SupplementationTrial methodologic qualityInfants fed formulaWeighted mean differenceSecondary subgroup analysisFatty acid supplementationMeasures of neurodevelopmentInfant Development scoresFed formulaPrimary outcomeSubgroup analysisUnsupplemented formulaMethodologic qualityInclusion criteriaPrematurity statusAcid supplementationSupplementation efficacySecondary analysisPublication biasMean differencePharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias
Carrasco M, Volkmar FR, Bloch MH. Pharmacologic Treatment of Repetitive Behaviors in Autism Spectrum Disorders: Evidence of Publication Bias. Pediatrics 2012, 129: e1301-e1310. PMID: 22529279, PMCID: PMC3340598, DOI: 10.1542/peds.2011-3285.Peer-Reviewed Original ResearchConceptsSerotonin receptor inhibitorsPublication biasTrial resultsPlacebo-controlled trialAutism spectrum disorderRepetitive behaviorsAvailable medicationsPatient agePharmacologic treatmentPrimary outcomeUnpublished trialsEgger's testReceptor inhibitorsMean improvementSpectrum disorderFunnel plotTrial designSecondary analysisTrial durationRating ScaleEfficacyTrialsTweedie's trimMedicationsTreatment